Generics and Biosimilars Market: global size, patent cliff and the India–GCC opportunity 2026–2032

Generics account for the large majority of prescriptions worldwide and biosimilars are the fastest-growing part of the market as a wave of biologic patents expires. Published estimates for the 2025 global generics (and in some scopes, biosimilars) market range from USD 514 bn to USD 515 bn; our central estimate is USD 515 bn, growing at about 5% to USD 739 bn by 2032.

The procurement story is biosimilars: adalimumab, trastuzumab, bevacizumab, rituximab, insulin glargine, enoxaparin and filgrastim already have multiple biosimilars; ustekinumab, denosumab, aflibercept, eculizumab, tocilizumab and omalizumab followed in 2024–26; semaglutide and others come later in the decade. Each switch programme typically saves 40–70% on the molecule. India is the largest manufacturing base for biosimilars outside Europe and the US; GCC tenders have begun to adopt them at scale.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 514 bn–USD 515 bn; differences are mostly scope.

Included: small-molecule generics and biosimilars sold globally; regional notes for the GCC and India. Excluded: originator biologics (reported as the reference), OTC where not generic. Segmentation: by type (generic, biosimilar), by therapy area, by region, by channel.

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• Patent cliff: USD 405 bn revenue at risk over five years (USD 180 bn small-molecule, USD 225 bn biologics); nearly 50 biologics lose exclusivity through 2030; at least 13 major drugs (Pharmaceutical Commerce)
• IQVIA: 118 biologics lose protection 2025-2034 (USD 232 bn opportunity); separate estimate USD 300 bn (~1/6 of industry revenue) loses exclusivity 2025-2030 (DIA Global Forum)
• Biosimilar launch prices typically 50% below reference (HHS 2025) or 40% (JAMA 2026); US biosimilar savings USD 20.2 bn in 2024 (DIA Global Forum)
• Small molecules lose ~90% share within months of expiry; biologics lose 30-70% in first year (DIA Global Forum)
• Generics are 90% of US prescriptions and saved USD 3.1 trn in 2014-2023 (Pharmaceutical Commerce)
• Biosimilars 2025: mAbs 47.35% of revenue, oncology 54.30%, hospitals 67.40%; Europe largest (36.65%), APAC fastest (23.10% CAGR) (Mordor Intelligence)
• Middle East & Africa holds 5.01% of global biosimilar market (2025) (DIA Global Forum)
• GCC imports 80-90% of medicines; GCC biologics USD 21.6 bn (2024) -> USD 102.9 bn (2035); UAE biologics CMO USD 84.9 mn (2024) -> USD 141.1 mn (2030) (PharmaKnowl)
• India supplies ~20% of global generic medicines and ~8% of global API industry; ~60,000 generic brands (PIB)
• Simple generics 60.74% of generics market; oral route 66.33%; North America 36.19% (2024) (Vision Research Reports)

GCC

Historically originator-heavy, the GCC is now adopting biosimilars through NUPCO, PureHealth and private-group tenders, with SFDA and MOHAP interchangeability positions evolving. Price gaps between originator (GCC) and biosimilar (India) of 60–90% make the business case obvious; the barriers are registration timing, clinician confidence and pharmacovigilance capacity.

India

Biocon, Dr Reddy’s, Intas, Zydus, Lupin, Reliance Life Sciences and others supply biosimilars domestically at a fraction of originator prices and export to regulated and semi-regulated markets; the domestic market has already switched most oncology and insulin volume.

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Hospital leaders: run a biosimilar switch programme molecule by molecule with P&T sign-off, a pharmacovigilance plan and a savings tracker reconciled to the ledger; the repository flags biosimilar-available lines.
• Manufacturers: GCC registration and tender readiness ahead of each patent expiry; supply reliability is the differentiator after price.
• Payers and insurers: formulary rules that prefer biosimilars are the single largest drug-cost lever available.

1. Vision Research Reports / Precedence Research via BioSpace, Generic Drugs Market Size to Hit USD 775.61 Billion by 2033 — biospace.com
2. Precedence Research via BioSpace, Generic Drugs Market Size is Expanding Around USD 670.82 Billion by 2030 — biospace.com
3. BCC Research, Global Markets for Generic Drugs (PHM009J) — bccresearch.com
4. Mordor Intelligence, Biosimilars Market Size and Share — mordorintelligence.com
5. IMARC Group, Global Biosimilar Market Expected to Grow at 22.90% During 2026-2034 — imarcgroup.com
6. BCC Research via ResearchAndMarkets / GlobeNewswire, Biosimilars: Global Markets - A $69.2 Billion Market by 2029 — globenewswire.com
7. DIA Global Forum, Expanding Access to Biosimilars: The Looming Patent Cliff — globalforum.diaglobal.org
8. Pharmaceutical Commerce, The $405 Billion Patent Cliff Demands Partnership — pharmaceuticalcommerce.com
9. Credence Research, MEA Biologics and Biosimilars Market — credenceresearch.com
10. PharmaKnowl, Biotechnology in Saudi Arabia and GCC countries — pharmaknowl.com
11. PIB, Government of India, Pharma sector backgrounder (March 2026) — static.pib.gov.in
12. Vision Research Reports / Precedence Research (generics) (2025-02) — USD 515.07 bn (2025) to USD 775.61 bn (2033), CAGR 5.25% (2025-2033); scope: Global generic drugs; US USD 138.18 bn (2024) growing 3.53% to USD 188.82 bn (2033) — source
13. Precedence Research (generics) (2022-11) — USD 439.37 bn (2022) to USD 670.82 bn (2030), CAGR 5.4% (2022-2030); scope: Global generic drugs; super generics expected >25% of market — source
14. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
15. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.